Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents
Platelet hyperactivity in type 2 diabetes: role of antiplatelet agents
复制标题
DOI：
10.3132/dvdr.2008.023
复制
发表时间：
2008-06-01
影响因子：
2.4
通讯作者：
Marshall, Sally M.
中科院分区：
文献类型：
--
作者：
Natarajan, Arun;Zaman, Azfar G.;Marshall, Sally M.
2 型糖尿病会增加动脉粥样硬化血栓形成的风险。糖尿病患者的血小板在基线和对激动剂的反应中表现出增加的活性，最终导致聚集增加。血小板表面粘附分子和受体的表达增加、血栓素和凝血酶的产生增加以及血小板钙稳态的紊乱都有据可查。由于动脉内血栓是由血小板引发的，限制急性血栓事件的策略主要集中在抗血小板药物上。阿司匹林仍然是抗血小板治疗的基石，但似乎对糖尿病的益处有限。噻吩并吡啶和血小板糖蛋白 Ilb/IIIa 受体抑制剂的使用已被证明对高危患者群体有益。本综述总结了糖尿病中不同的血小板异常特征以及当前使用的抗血小板药物的作用。
Type 2 diabetes mellitus increases atherothrombotic risk. Platelets in individuals with diabetes show increased activity at baseline and in response to agonists, ultimately leading to increased aggregation. Increased expression of platelet surface adhesion molecules and receptors, enhanced production of thromboxane and thrombin and disturbances in platelet calcium homeostasis are well documented. As intra-arterial thrombi are initiated by platelets, strategies to limit acute thrombotic events have largely focused on antiplatelet agents. Aspirin remains the cornerstone of antiplatelet therapy but appears to have limited benefit in diabetes. Use of thienopyridines and platelet glycoprotein Ilb/IIIa receptor inhibitors has been shown to benefit high-risk patient populations. This review summarises the different platelet abnormalities characterised in diabetes and the role of currently used antiplatelet agents.